Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes

Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018;41(5):917–28. https://doi.org/10.2337/dci18-0007.

Waters H GM: America’s obesity crisis: the health and economic costs of excess weight. Milken Institute. https://www.milkeninstitute.org/reports/americas-obesity-crisis-health-and-economic-costs-excess-weight (October 2018). Accessed November 22 2021.

Tseng CH. Mortality and causes of death in a national sample of diabetic patients in Taiwan. Diabetes Care. 2004;27(7):1605–9. https://doi.org/10.2337/diacare.27.7.1605.

Article  PubMed  Google Scholar 

McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2(10):843–51. https://doi.org/10.1016/s2213-8587(14)70031-2.

Article  CAS  PubMed  Google Scholar 

Moss SE, Klein R, Klein BE. Cause-specific mortality in a population-based study of diabetes. Am J Public Health. 1991;81(9):1158–62. https://doi.org/10.2105/ajph.81.9.1158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kranenburg G, van der Graaf Y, van der Leeuw J, Nathoe HM, de Borst GJ, Kappelle LJ, et al. The relation between HbA1c and cardiovascular events in patients with type 2 diabetes with and without vascular disease. Diabetes Care. 2015;38(10):1930–6. https://doi.org/10.2337/dc15-0493.

Article  CAS  PubMed  Google Scholar 

Sarwar N, Aspelund T, Eiriksdottir G, Gobin R, Seshasai SR, Forouhi NG, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010;7(5):e1000278. https://doi.org/10.1371/journal.pmed.1000278.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirst JA, Farmer AJ, Ali R, Roberts NW, Stevens RJ. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446–54. https://doi.org/10.2337/dc11-1465.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Apolzan JW, Venditti EM, Edelstein SL, Knowler WC, Dabelea D, Boyko EJ, et al. Long-term weight loss with metformin or lifestyle intervention in the diabetes prevention program outcomes study. Ann Intern Med. 2019;170(10):682–90. https://doi.org/10.7326/M18-1605.

Article  PubMed  PubMed Central  Google Scholar 

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65.

Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221–8. https://doi.org/10.1111/j.1463-1326.2010.01349.x.

Article  CAS  PubMed  Google Scholar 

Medicine. USNLo: Investigation of metformin in pre-diabetes on atherosclerotic cardiovascular outcomes. https://clinicaltrials.gov/show/NCT02915198 Accessed 23 November 2021.

Hasan SS, Aslam Q, Islam I, Kow CS, Babar ZUD. Metformin-based single pill drug combinations for type 2 diabetes in primary care England: a time trend analysis. Prim Care Diabetes. 2022;16(2):271–8. https://doi.org/10.1016/j.pcd.2022.01.008.

Article  PubMed  Google Scholar 

Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36(1):14–37. https://doi.org/10.2337/cd17-0119.

Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. https://doi.org/10.1016/s0140-6736(19)31149-3.

Article  CAS  PubMed  Google Scholar 

Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29. https://doi.org/10.1016/s0140-6736(18)32261-x.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. https://doi.org/10.1056/NEJMoa1607141.

Article  CAS  PubMed  Google Scholar 

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. https://doi.org/10.1056/NEJMoa1603827.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neal B, Perkovic V, Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(21):2099. https://doi.org/10.1056/NEJMc1712572.

Article  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.

Article  CAS  PubMed  Google Scholar 

• Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D, et al. Effects of long-term metformin and lifestyle interventions on cardiovascular events in the diabetes prevention program and its outcome study. Circulation. 2022;145(22):1632–41. https://doi.org/10.1161/circulationaha.121.056756. This study provides evidence that metformin does not have CV benefits which propel the T2DM treatment towards SGLT2is and GLP1-RAs.

Article  CAS  PubMed  Google Scholar 

Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015;24(5):463–9. https://doi.org/10.1097/MNH.0000000000000152.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5(6):632–44. https://doi.org/10.1016/j.jacbts.2020.02.004.

Article  PubMed  PubMed Central  Google Scholar 

Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61. https://doi.org/10.1056/NEJMoa2107038.

Article  CAS  PubMed  Google Scholar 

Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–35. https://doi.org/10.1056/NEJMoa2004967.

Article  CAS  PubMed  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.

Article  CAS  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. https://doi.org/10.1056/NEJMoa1911303.

Article  CAS  PubMed  Google Scholar 

Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–24. https://doi.org/10.1056/NEJMoa2022190.

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.

Article  CAS  PubMed  Google Scholar 

Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643–58. https://doi.org/10.1161/circulationaha.117.030012.

Article  CAS  PubMed  Google Scholar 

Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687–93. https://doi.org/10.2337/dc15-0843.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Legaspi R, Narciso P. Euglycemic diabetic ketoacidosis due to gastroparesis, a local experience. J Ark Med Soc. 2015;112(5):62–3.

PubMed  Google Scholar 

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–28. https://doi.org/10.1056/NEJMoa2030183.

Article  CAS  PubMed  Google Scholar 

Li N, Lv D, Zhu X, Wei P, Gui Y, Liu S, et al. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med (Lausanne). 2021;8: 728089. https://doi.org/10.3389/fmed.2021.728089.

Article  PubMed  Google Scholar 

Cavender MA, Norhammar A, Birkeland KI, Jørgensen ME, Wilding JP, Khunti K, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497–506. https://doi.org/10.1016/j.jacc.2018.01.085.

Article  CAS  PubMed  Google Scholar 

Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628–39. https://doi.org/10.1016/j.jacc.2018.03.009.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896–907. https://doi.org/10.1056/NEJMoa2108269.

Article  CAS 

留言 (0)

沒有登入
gif